Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.16
NAS:SRPT's Cash-to-Debt is ranked lower than
71% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:SRPT: 2.16 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SRPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.16  Med: 157.99 Max: No Debt
Current: 2.16
2.16
No Debt
Equity-to-Asset 0.56
NAS:SRPT's Equity-to-Asset is ranked lower than
63% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:SRPT: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SRPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.09  Med: 0.85 Max: 0.98
Current: 0.56
-0.09
0.98
Debt-to-Equity 0.63
NAS:SRPT's Debt-to-Equity is ranked lower than
72% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. NAS:SRPT: 0.63 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SRPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68  Med: 0.09 Max: 2.07
Current: 0.63
-0.68
2.07
Debt-to-EBITDA -6.58
NAS:SRPT's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. NAS:SRPT: -6.58 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:SRPT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.4  Med: -0.08 Max: -0.02
Current: -6.58
-12.4
-0.02
Piotroski F-Score: 3
Altman Z-Score: 9.87
Beneish M-Score: -0.34
WACC vs ROIC
15.20%
-131.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -74.41
NAS:SRPT's Operating Margin % is ranked higher than
55% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:SRPT: -74.41 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SRPT' s Operating Margin % Range Over the Past 10 Years
Min: -17572.55  Med: -89.5 Max: -71.16
Current: -74.41
-17572.55
-71.16
Net Margin % -89.64
NAS:SRPT's Net Margin % is ranked higher than
52% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:SRPT: -89.64 )
Ranked among companies with meaningful Net Margin % only.
NAS:SRPT' s Net Margin % Range Over the Past 10 Years
Min: -17560.26  Med: -233.99 Max: -4.93
Current: -89.64
-17560.26
-4.93
ROE % -32.39
NAS:SRPT's ROE % is ranked higher than
56% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:SRPT: -32.39 )
Ranked among companies with meaningful ROE % only.
NAS:SRPT' s ROE % Range Over the Past 10 Years
Min: -309.2  Med: -100.95 Max: -9
Current: -32.39
-309.2
-9
ROA % -21.19
NAS:SRPT's ROA % is ranked higher than
62% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:SRPT: -21.19 )
Ranked among companies with meaningful ROA % only.
NAS:SRPT' s ROA % Range Over the Past 10 Years
Min: -93.53  Med: -59.76 Max: -4.62
Current: -21.19
-93.53
-4.62
ROC (Joel Greenblatt) % -69.28
NAS:SRPT's ROC (Joel Greenblatt) % is ranked higher than
69% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:SRPT: -69.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SRPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -978.9  Med: -512.65 Max: -57.75
Current: -69.28
-978.9
-57.75
3-Year Revenue Growth Rate 120.80
NAS:SRPT's 3-Year Revenue Growth Rate is ranked higher than
96% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:SRPT: 120.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SRPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.3  Med: 9.1 Max: 343.4
Current: 120.8
-73.3
343.4
3-Year EBITDA Growth Rate 43.30
NAS:SRPT's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:SRPT: 43.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SRPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.7  Med: -3.6 Max: 43.3
Current: 43.3
-61.7
43.3
3-Year EPS without NRI Growth Rate 36.70
NAS:SRPT's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NAS:SRPT: 36.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SRPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -213.5  Med: 0 Max: 62.2
Current: 36.7
-213.5
62.2
GuruFocus has detected 7 Warning Signs with Sarepta Therapeutics Inc NAS:SRPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SRPT's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

SRPT Guru Trades in Q3 2017

Joel Greenblatt 9,268 sh (New)
Ken Fisher 42,642 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen 1,645,275 sh (-18.77%)
» More
Q4 2017

SRPT Guru Trades in Q4 2017

Ken Fisher 42,648 sh (+0.01%)
Steven Cohen 200,000 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 579,757 sh (-64.76%)
» More
Q1 2018

SRPT Guru Trades in Q1 2018

Pioneer Investments 49,662 sh (New)
Jim Simons 255,778 sh (New)
Steven Cohen 50,000 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Steven Cohen Sold Out
Ken Fisher 39,231 sh (-8.01%)
» More
Q2 2018

SRPT Guru Trades in Q2 2018

Paul Tudor Jones 40,761 sh (New)
Joel Greenblatt 9,924 sh (New)
Louis Moore Bacon 9,000 sh (New)
Steven Cohen 265,761 sh (New)
Pioneer Investments 103,418 sh (+108.24%)
Jim Simons 495,478 sh (+93.71%)
Steven Cohen 25,000 sh (unchged)
Ken Fisher 33,187 sh (-15.41%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -15.41%$71.74 - $153.69 $ 154.5664%33,187
Joel Greenblatt 2018-06-30 New Buy0.02%$71.74 - $153.69 $ 154.5664%9,924
Ken Fisher 2018-03-31 Reduce -8.01%$54.02 - $82.27 $ 154.56132%39,231
Ken Fisher 2017-12-31 Add 0.01%$47.64 - $56.75 $ 154.56192%42,648
Joel Greenblatt 2017-12-31 Sold Out 0.01%$47.64 - $56.75 $ 154.56192%0
Ken Fisher 2017-09-30 New Buy$33.89 - $47.15 $ 154.56287%42,642
Joel Greenblatt 2017-09-30 New Buy0.01%$33.89 - $47.15 $ 154.56287%9,268
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Sarepta Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XKRX:128940, NAS:AGIO, TSE:4587, SZSE:300347, NAS:UTHR, SZSE:000661, XKRX:215600, XAMS:GLPG, HKSE:01530, NAS:IONS, OSTO:SOBI, NAS:TECH, HKSE:01548, BOM:532523, SZSE:002007, XBRU:ABLX, SHSE:603233, NAS:FGEN, NAS:LOXO, NAS:EXEL » details
Traded in other countries:AB3A.Germany,
Headquarter Location:USA
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Top Ranked Articles about Sarepta Therapeutics Inc

Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen
Parent Project Muscular Dystrophy and Sarepta Therapeutics Partner to Launch Duchenne Outcomes Research Interchange, a Patient-Data Warehouse Serving the Entire Duchenne Community
Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Alnylam: Officially First to Market With RNAi Therapy Competition is expected to be tough
After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) brought the world’s first RNAi treatment, known as Onpattro, to market. Read more...
Weekly CEO Buys Highlight Insiders invest in Penn National Gaming, Sarepta Therapeutics, News Corp., e.l.f. Beauty and New Media Investment Group
According to GuruFocus insider data, these are the largest CEO buys of the past week. Read more...
Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools

Ratios

vs
industry
vs
history
PB Ratio 14.68
SRPT's PB Ratio is ranked lower than
85% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. SRPT: 14.68 )
Ranked among companies with meaningful PB Ratio only.
SRPT' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 5.56 Max: 238.78
Current: 14.68
2
238.78
PS Ratio 41.02
SRPT's PS Ratio is ranked lower than
70% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SRPT: 41.02 )
Ranked among companies with meaningful PS Ratio only.
SRPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 22.82 Max: 39930
Current: 41.02
1.56
39930
EV-to-EBIT -127.38
SRPT's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. SRPT: -127.38 )
Ranked among companies with meaningful EV-to-EBIT only.
SRPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -144.3  Med: -6.1 Max: 47.2
Current: -127.38
-144.3
47.2
EV-to-EBITDA -146.10
SRPT's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. SRPT: -146.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -187.8  Med: -6.35 Max: 42.8
Current: -146.1
-187.8
42.8
EV-to-Revenue 40.44
SRPT's EV-to-Revenue is ranked lower than
65% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. SRPT: 40.44 )
Ranked among companies with meaningful EV-to-Revenue only.
SRPT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 19.95 Max: 58632.1
Current: 40.44
0.8
58632.1
Current Ratio 10.88
SRPT's Current Ratio is ranked higher than
78% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SRPT: 10.88 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.76  Med: 7.11 Max: 36.25
Current: 10.88
0.76
36.25
Quick Ratio 9.89
SRPT's Quick Ratio is ranked higher than
77% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. SRPT: 9.89 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 7.11 Max: 36.25
Current: 9.89
0.76
36.25
Days Inventory 1.00
SRPT's Days Inventory is ranked higher than
98% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. SRPT: 1.00 )
Ranked among companies with meaningful Days Inventory only.
SRPT' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 12772.64 Max: 23152.2
Current: 1
1
23152.2
Days Sales Outstanding 63.60
SRPT's Days Sales Outstanding is ranked higher than
51% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. SRPT: 63.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22  Med: 77.47 Max: 1158.5
Current: 63.6
28.22
1158.5
Days Payable 334.96
SRPT's Days Payable is ranked higher than
87% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. SRPT: 334.96 )
Ranked among companies with meaningful Days Payable only.
SRPT' s Days Payable Range Over the Past 10 Years
Min: 334.96  Med: 53857.92 Max: 107295.54
Current: 334.96
334.96
107295.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.20
SRPT's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. SRPT: -16.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -20.4 Max: -11.6
Current: -16.2
-27.6
-11.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 25.59
SRPT's Price-to-Net-Cash is ranked lower than
80% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. SRPT: 25.59 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.03  Med: 6.53 Max: 72.6
Current: 25.59
3.03
72.6
Price-to-Net-Current-Asset-Value 17.35
SRPT's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. SRPT: 17.35 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.95  Med: 6.2 Max: 42
Current: 17.35
2.95
42
Price-to-Tangible-Book 14.99
SRPT's Price-to-Tangible-Book is ranked lower than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. SRPT: 14.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.41  Med: 4.88 Max: 395
Current: 14.99
2.41
395
Price-to-Median-PS-Value 1.80
SRPT's Price-to-Median-PS-Value is ranked lower than
73% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. SRPT: 1.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 3.26 Max: 1605.5
Current: 1.8
0.09
1605.5
Earnings Yield (Greenblatt) % -0.77
SRPT's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. SRPT: -0.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -94.6  Med: -15.75 Max: 2.9
Current: -0.77
-94.6
2.9

More Statistics

Revenue (TTM) (Mil) $241.36
EPS (TTM) $ -3.39
Beta2.07
Volatility48.36%
52-Week Range $42.97 - 176.50
Shares Outstanding (Mil)66.44

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 302 430 616 1,395
EBIT (Mil $) -240 -161 -6 1,344
EBITDA (Mil $) -231 -150 10 1,396
EPS ($) -3.29 -1.72 0.34 13.60
EPS without NRI ($) -3.29 -1.72 0.34 13.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}